Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis

Expert Review of Respiratory Medicine

Volumn 9, Issue 1, 2015, Pages 13-22

  Stockmann, Chris ^a,b   Hillyard, Brad ^a   Ampofo, Krow ^a   Spigarelli, Michael G ^a,b   Sherwin, Catherine Mt ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Aerosolized antibiotics; anti pseudomonal antimicrobial; antibacterial; antibiotic; fluoroquinolones; MP 376; pulmonary exacerbations

Indexed keywords

LEVOFLOXACIN; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; APPENDICITIS; BIOFILM; COUGHING; CYSTIC FIBROSIS; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; HEADACHE; HEMOPTYSIS; HUMAN; LUNG FUNCTION; MAINTENANCE THERAPY; NONHUMAN; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SPUTUM; SYMPTOMATOLOGY; WHEEZING; ANIMAL; CHRONIC DISEASE; COMPLICATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; LUNG; MEDICINAL CHEMISTRY; MICROBIOLOGY; PATHOGENICITY; PATHOPHYSIOLOGY; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; TIME; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CHRONIC DISEASE; CYSTIC FIBROSIS; HUMANS; LEVOFLOXACIN; LUNG; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SPUTUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 84920989635     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2015.986469     Document Type: Review

References (59)

1. Zobell JT, Young DC, Waters CD, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatr Pulmonol 2012; 47(12):1147-58
2. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002;15(2):194-222
3. Schwartz M, Johansen HK, Koch C, Brandt NJ. Frequency of the delta F508 mutation on cystic fibrosis chromosomes in Denmark. Hum Genet 1990;85(4):427-8
4. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168(8):918-51
5. Flume PA, Robinson KA, O'Sullivan BP, et al. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009;54(4):522-37
6. Meluleni GJ, Grout M, Evans DJ, Pier GB. Mucoid Pseudomonas aeruginosa growing in a biofilm in vitro are killed by opsonic antibodies to the mucoid exopolysaccharide capsule but not by antibodies produced during chronic lung infection in cystic fibrosis patients. J Immunol 1995;155(4): 2029-38
7. Brooun A, Liu S, Lewis K. A dose-response study of antibiotic resistance in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2000;44(3): 640-6
8. Xu KD, McFeters GA, Stewart PS. Biofilm resistance to antimicrobial agents. Microbiology 2000;146(Pt 3):547-9
9. Bittar F, Richet H, Dubus JC, et al. Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients. PLoS One 2008;3(8):e2908
10. Bhatt JM. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev 2013;22(129):205-16
11. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340(1):23-30
12. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34(2):91-100
13. Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: best Practice guidelines. J Cyst Fibros 2014;13(Suppl 1):S23-42
14. Mendelman PM, Smith AL, Levy J, et al. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis 1985;132(4):761-5
15. Eisenberg J, Pepe M, Williams-Warren J, et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest 1997;111(4):955-62
16. King P, Lomovskaya O, Griffith DC, et al. In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis. Antimicrob Agents Chemother 2010;54(1): 143-8
17. Stockmann C, Sherwin CM, Ampofo K, Spigarelli MG. Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis. Ther Adv Respir Dis 2014;8(1):13-21
18. Geller DE, Madge S. Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis. Respir Med 2011;105(Suppl 2):S24-31
19. Kesser KC, Geller DE. New aerosol delivery devices for cystic fibrosis. Respir Care 2009; 54(6):754-67.discussion 767-758
20. Geller DE. The science of aerosol delivery in cystic fibrosis. Pediatr Pulmonol 2008; 43(Suppl 9):S5-S17
21. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997;32(2):101-19
22. Hooper DC, Wolfson JS. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob Agents Chemother 1985;28(5):716-21
23. Stockmann C, Sherwin CM, Zobell JT, et al. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones. Pediatr Pulmonol 2013;48(3):211-20
24. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997;40(5):639-51
25. Critchley IA, Jones ME, Heinze PD, et al. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. Clin Microbiol Infect 2002;8(4):214-21
26. Imamura M, Shibamura S, Hayakawa I, Osada Y. Inhibition of DNA gyrase by optically active ofloxacin. Antimicrob Agents Chemother 1987;31(2):325-7
27. Gellert M. DNA topoisomerases. Ann Rev Biochem 1981;50:879-910
28. Akasaka T, Tanaka M, Yamaguchi A, Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 2001;45(8): 2263-8
29. Gilligan PH. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991;4(1):35-51
30. Jorgensen KM, Wassermann T, Jensen PO, et al. Sublethal ciprofloxacin treatment leads to rapid development of high-level ciprofloxacin resistance during long-term experimental evolution of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2013;57(9):4215-21
31. Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 1996; 23(Suppl 1):S19-24
32. Ryan G, Singh M, Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 2011 (3):CD001021
33. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis 2003;3(6):359-71
34. Tsivkovskii R, Sabet M, Tarazi Z, et al. Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections. FEMS Immunol Med Microbiol 2011; 61(2):141-6
35. Jacquot J, Tabary O, Le Rouzic P, Clement A. Airway epithelial cell inflammatory signalling in cystic fibrosis. Int J Biochem Cell Biol 2008;40(9):1703-15
36. Geller DE, Flume PA, Griffith DC, et al. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother 2011;55(6):2636-40 10 patients with cystic fibrosis.
37. Sabet M, Miller CE, Nolan TG, et al. Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53(9):3923-8
38. Valle MJ, Gonzalez Lopez F, Sanchez Navarro A. Pulmonary versus systemic delivery of levofloxacin. The isolated lung of the rat as experimental approach for assessing pulmonary inhalation. Pulmonary Pharmacol Ther 2008;21(2):298-303
39. Griffith D, Saechao B, Chen L, et al. Pulmonary and plasma pharmacokinetics of levofloxacin following administration of MP-376 in rats. Pediatr Pulmonol 2007; 42(S30):303
40. Griffith DC, Hansen C, Pressler T, et al. Single-dose pharmacokinetics of aerosol MP-376 (levofloxacin solution for inhalation) in cystic fibrosis patients: PK-PD implications. J Cyst Fibros 2008;7: S26
41. Geller D, Kesser KC, Surber M, et al. Pharmacokinetics of oral levofloxacin (LVX) in stable adult CF patients. Pediatr Pulmonol 2006;41(S29):328
42. King P, Citron DM, Griffith DC, et al. Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients. Diagn Microbiol Infect Dis 2010; 66(2):181-6
43. Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109(3):317-25
44. Geller DE, Flume PA, Staab D, et al. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011;183(11):1510-16
45. Geller DE, Flume P, Schwab R, et al. A Phase I. Safety, Tolerability, and Pharmacokinetic (PK) Study of MP-376 (Levofloxacin Solution for Inhalation) in Stable Cystic Fibrosis (CF) Patients [abstract]. Pediatr Pulmonl 2008; 43(Suppl 31):315, Abstract no: 321
46. Griffith DC, Corcoran E, Lofland D, et al. Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy? Antimicrob Agents Chemother 2006;50(5):1628-32
47. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37(5): 1073-81
48. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179(5): 1190-6
49. Dudley MN, Loutit J, Griffith DC. Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Curr Opin Biotechnol 2008;19(6):637-43
50. MP-376 (AeroquinTM, Levofloxacin for Inhalation) in patients with cystic fibrosis. Available from: http://clinicaltrials.gov/show/NCT01180634
51. Trial of aeroquin versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients. Available from: http://clinicaltrials.gov/show/NCT01270347
52. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335(3):179-88
53. Touw DJ, Brimicombe RW, Hodson ME, et al. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995;8(9):1594-604
54. Lee CK, Boyle MP, Diener-West M, et al. Levofloxacin pharmacokinetics in adult cystic fibrosis. Chest 2007;131(3):796-802
55. Kearns GL, Rubino CM, Griffith DC, et al. Levofloxacin Pharmacokinetics (PK) After Administration of MP-376 (Levofloxacin Inhalation Solution; Aeroquin) in Children with Cystic Fibrosis (CF). Abstract J Cyst Fibros 2011;10(Suppl 1):S23, Abstract no: 88
56. Safety, tolerability and pharmacokinetics of MP-376 administered for 14 days to stable pediatric (CF) patients. Available from: http://clinicaltrials.gov/show/NCT00840333
57. Azoicai D, Antoniu SA. MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections. Expert Opin Invest Drugs 2013; 22(2):267-76
58. Sanders DB, Bittner RC, Rosenfeld M, et al. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011;46(4):393-400
59. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182(5):627-32